• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ASP-3026 Drug Record

  • Summary
  • Interactions
  • Claims
  • ASP-3026 chembl:CHEMBL3545360 Antineoplastic

    Alternate Names:

    ASP 3026
    ASP-3026
    ASP3026

    Drug Info:

    Drug Class Kinase Inhibitors
    Pharmaceutical Developer Astellas Pharma
    Source Reported Drug Name(s) ASP3026
    Drug Class ALK Inhibitor
    (3 More Sources)

    Publications:

    Amin et al., 2016, TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors., Oncotarget
    Ceccon et al., 2015, Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma., Mol. Cancer Res.
    Mologni et al., 2015, NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922., Oncotarget
    Katayama et al., 2014, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib., Clin. Cancer Res.
  • ASP-3026   EML4

    Interaction Score: 4.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    25228534 27009859


    Sources:
    JAX-CKB

  • ASP-3026   NPM1

    Interaction Score: 4.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type anaplastic large cell lymphoma
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    27009859 25749034 25421750


    Sources:
    JAX-CKB

  • ASP-3026   ALK

    Interaction Score: 2.58

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Lung
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant

    PMIDs:
    27009859 25421750 25749034 25228534


    Sources:
    MyCancerGenome JAX-CKB ChemblInteractions CancerCommons TTD

  • ASP-3026   ROS1

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Lung

    PMIDs:
    None found


    Sources:
    CancerCommons

  • MyCancerGenome: ASP3026

    • Version: 20-Jun-2017

    Alternate Names:
    ASP3026 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • CancerCommons: ASP3026

    • Version: 25-July-2013

    Alternate Names:
    ASP3026 PubChem Drug Name
    25134326 PubChem Drug ID
    ASP3026 Drug Trade Name

    Drug Info:
    Drug Class ALK Inhibitor
    Source Reported Drug Name(s) ASP3026
    Pharmaceutical Developer Astellas Pharma

    Publications:

  • JAX-CKB: ASP3026

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Amin et al., 2016, TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors., Oncotarget
    Katayama et al., 2014, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib., Clin. Cancer Res.
    Mologni et al., 2015, NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922., Oncotarget

  • TTD: ASP3026

    • Version: 2020.06.01

    Alternate Names:
    D09GEK TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3545360

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3545360

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: ASP-3026

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21